{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:29:18Z","timestamp":1771460958046,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jaad.2020.11.042","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:40:44Z","timestamp":1615509644000},"page":"1010-1014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Retrospective analysis of adverse events with dupilumab reported to the United States Food and Drug Administration"],"prefix":"10.1016","volume":"84","author":[{"given":"Yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph L.","family":"Jorizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2020.11.042_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaip.2019.06.044","article-title":"Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection","volume":"8","author":"Fishbein","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.jaad.2020.11.042_bib2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.12788\/j.sder.2017.036","article-title":"Atopic dermatitis: pathogenesis","volume":"36","author":"Guttman-Yassky","year":"2017","journal-title":"Semin Cutan Med Surg"},{"issue":"5","key":"10.1016\/j.jaad.2020.11.042_bib3","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jaip.2019.01.005","article-title":"Atopic dermatitis in US adults: from population to health care utilization","volume":"7","author":"Silverberg","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.jaad.2020.11.042_bib4","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1016\/j.jaip.2019.05.055","article-title":"Pain is a common and burdensome symptom of atopic dermatitis in United States adults","volume":"7","author":"Silverberg","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.jaad.2020.11.042_bib5","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jaad.2017.08.043","article-title":"Sleep disturbance in children with moderate\/severe atopic dermatitis: a case-control study","volume":"78","author":"Fishbein","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.11.042_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-3-319-64804-0_6","article-title":"The psychosocial impact of atopic dermatitis","volume":"1027","author":"Gochnauer","year":"2017","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"10.1016\/j.jaad.2020.11.042_bib7","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/bjd.17683","article-title":"Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults","volume":"181","author":"Silverberg","year":"2019","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.11.042_bib8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jaci.2012.10.041","article-title":"Mental health comorbidity in patients with atopic dermatitis","volume":"131","author":"Yaghmaie","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.jaad.2020.11.042_bib9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/DER.0000000000000526","article-title":"Association of atopic dermatitis with bacterial, fungal, viral, and sexually transmitted skin infections","volume":"31","author":"Ren","year":"2020","journal-title":"Dermatitis"},{"issue":"1","key":"10.1016\/j.jaad.2020.11.042_bib10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.iac.2016.08.015","article-title":"Infectious complications in atopic dermatitis","volume":"37","author":"Sun","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"issue":"3","key":"10.1016\/j.jaad.2020.11.042_bib11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3390\/jcm9030791","article-title":"Clinical response and quality of life in patients with severe atopic dermatitis treated with dupilumab: a single-center real-life experience","volume":"9","author":"Ferrucci","year":"2020","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.jaad.2020.11.042_bib12","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.14888","article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II","volume":"32","author":"Wollenberg","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10086","key":"10.1016\/j.jaad.2020.11.042_bib14","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.jaad.2020.11.042_bib15","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jaad.2020.11.042_bib17","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.11.042_bib18","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/bjd.18255","article-title":"Keeping an eye on the ocular problems in dupilumab clinical trials","volume":"181","author":"Chu","year":"2019","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.11.042_bib19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2340\/00015555-3121","article-title":"Eye complications during dupilumab treatment for severe atopic dermatitis","volume":"99","author":"Ivert","year":"2019","journal-title":"Acta Derm Venereol"},{"issue":"11","key":"10.1016\/j.jaad.2020.11.042_bib20","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.1111\/jdv.15755","article-title":"Pathomechanism of dupilumab-associated inflammatory eye symptoms","volume":"33","author":"Wohlrab","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2020.11.042_bib21","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jaip.2018.01.034","article-title":"Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment","volume":"6","author":"Wollenberg","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3 Suppl 1","key":"10.1016\/j.jaad.2020.11.042_bib22","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.jaad.2017.12.022","article-title":"Dupilumab: a review of its use in the treatment of atopic dermatitis","volume":"78","author":"Gooderham","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.11.042_bib23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2249.1995.tb03796.x","article-title":"Measurement of IL-4 in tears of patients with seasonal allergic conjunctivitis and vernal keratoconjunctivitis","volume":"102","author":"Fujishima","year":"1995","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"10.1016\/j.jaad.2020.11.042_bib24","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jamadermatol.2018.2690","article-title":"Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis","volume":"154","author":"Treister","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.11.042_bib25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2013.02.010","article-title":"Why is eczema herpeticum unexpectedly rare?","volume":"98","author":"Leung","year":"2013","journal-title":"Antivir Res"},{"issue":"2","key":"10.1016\/j.jaad.2020.11.042_bib26","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jaci.2009.05.020","article-title":"Phenotype of atopic dermatitis subjects with a history of eczema herpeticum","volume":"124","author":"Beck","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.jaad.2020.11.042_bib27","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1067\/S0190-9622(03)00896-X","article-title":"Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases","volume":"49","author":"Wollenberg","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.11.042_bib28","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.intimp.2017.11.031","article-title":"Adverse events of\u00a0Dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis","volume":"54","author":"Ou","year":"2018","journal-title":"Int Immunopharmacol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220330875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220330875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:59:01Z","timestamp":1759273141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962220330875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0190962220330875"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.11.042","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retrospective analysis of adverse events with dupilumab reported to the United States Food and Drug Administration","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.11.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}